|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||37.91 - 40.30|
|52 Week Range||24.00 - 108.77|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||4.55|
|Expense Ratio (net)||1.12%|
Here is a look at ETFs that currently offer attractive short selling opportunities. The ETFs included in this list are rated as sell candidates for two reasons. First, each of these funds is deemed to be in a downtrend based on the fact that its 50-day moving average is below its 200-day moving average, which are popular indicators for gauging long-term and medium-term trends, respectively. Second, each of these ETFs is also trading above its 20-day moving average, thereby offering a near-term 'sell on the pop' opportunity given the longer-term downtrend at hand. Note that this prospects list also features a liquidity screen by excluding ETFs with average trading volumes below the one million shares mark. As always, investors of all experience levels are advised to use stop-loss orders and practice disciplined profit-taking techniques. To get access to all ETFdb.com premium content, sign up for a free 14-day trial to ETFdb.com Pro.
With one of the industry's marquee conferences recently ending, traders may want to consider the Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) and the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). The American Society of Clinical Oncology Annual Meeting ended this week, which could bring CURE and LABU into focus for active traders.
For the past month, leveraged exchange-traded fund (ETF) traders have been feasting off opportunities in gold, biotech, large caps, and semiconductors as the U.S.-China trade deal went awry. The flight ...
Exchange-traded funds (ETFs) are often aimed at conservative investors with long-term time horizons. Many of the largest ETFs on the market today are designed to provide cost-effective exposure to basic asset classes, such as domestic stocks, international equities and high-grade government bonds.Another selling point of a slew of ETFs to buy is that these funds feature broad lineups of stocks, a strategy that reduces concentration risk while eliminating the need for stock picking. Bottom line: may of the top ETFs to buy are inexpensive and easy to understand, selling points that were the foundation of the ETF industry two decades ago and traits that are likely to continue driving the industry's exponential growth.However, the ETF business is evolving and that evolution has led to the introductions of products aimed at more risk-tolerant traders and investors. Some of the better ETFs to buy for more adventurous investors include thematic funds while others are designed to be more tactical in nature.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Strong Buy Stocks That Tick All the Boxes Put it this way: if you're an investor with an adventurous spirit, there are plenty of ETFs to buy, but in many cases, that does not mean an investor should take on high levels of risk for extended periods of time. For investors looking to juice their returns or simply take on some added risk, here are some ETFs to buy. Best ETFs to Buy for Gamblers: ProShares UltraShort QQQ (QID)Expense Ratio: 0.95% per year, or $95 on a $10,000 investment.The ProShares UltraShort QQQ (NYSEARCA:QID) is designed to deliver double the daily inverse returns of the widely followed Nasdaq-100 Index, so if that index declines by 1% on a particular day, QID should rise by 2%.In other words, QID is a bad ETF to buy when the Nasdaq-100 is going up, something that tech-heavy benchmark has made a habit of doing over the course of the past decade. The current market environment clearly favors growth and technology stocks, two of the fortes of the Nasdaq-100, making QID an ETF to buy for contrarians or those looking to hedge long positions in Nasdaq-100 funds.In either case, investors should note QID and other leveraged ETFs are intended for short-term traders, not to be held for long holding periods, because the longer a leveraged ETF like QID is held, the more the chances increase that the fund will deviate from its stated objective.Interestingly, market participants have added nearly $181 million to QID this year. Global X MSCI Greece ETF (GREK)Expense Ratio: 0.59%The Global X MSCI Greece ETF (NYSEARCA:GREK) is the only U.S.-listed ETF dedicated to Greek equities. After years of being saddled by austerity measures and borrowing billions from the International Monetary Fund (IMF) and the European Union (EU), Greece is finally on the right fiscal path.GREK is up nearly 22% year-to-date, indicating investors view this as an ETF to buy."In Q1, the markets were up 15.2% and forecasts put 2019 GDP growth at annualized 2.4%, versus Europe at just 1.3%," said Global X in a recent research note. "Greece's improving growth prospects could portend the start of a virtuous cycle for Greece, making it a standout against the weak backdrop of a sluggish Europe." * 7 Energy Stocks to Buy to Light Up Your Portfolio What makes GREK a risky ETF to buy is, among other factors, a standard deviation of 24%, which is well above the comparable metric on emerging markets and Eurozone benchmarks. Those are relevant comparisons because Greece is a Eurozone member and classified as an emerging market. VanEck Vectors Junior Gold Miners ETF (GDXJ)Expense Ratio: 0.53%Among risky industry and sector ETFs to buy, mining funds are certainly part of that conversation and precious metals mining funds, such as the VanEck Vectors Junior Gold Miners ETF (NYSEARCA:GDXJ) are among the best ETFs to buy for risk-tolerant investors.GDXJ is a fine ETF to buy for an active, risk-aware trader looking to make a bet on rising gold prices. One of the risks, however, with gold mining ETFs is that the funds are not always responsive to higher bullion prices. Amplifying the risk profile is that when gold prices decline, shares of miners often overshoot spot gold's declines.Add all that into the wrapper of a small-cap fund and GDXJ is a volatile ETF to buy. The fund's standard deviation of more than 31% is well above that of basic gold funds and traditional small-cap ETFs. iPath Global Carbon ETN (GRN)Expense Ratio: 0.75%The iPath Global Carbon ETN (NYSEARCA:GRN) definitely is not a good ETF for all investors. This niche, lightly traded exchange-traded note (ETN) tracks the Barclays Global Carbon II TR USD Index.That index "is designed to measure the performance of the most liquid carbon-related credit plans. Each carbon-related credit plan included in the index is represented by the most liquid instrument available in the marketplace. The index expects to incorporate new carbon-related credit plans as they develop around the world," according to the issuer. * 10 Cheap Stocks to Buy Now While GRN has low correlations to traditional asset classes, the fund is not for conservative investors due to its history of high volatility. Not to mention, most investors can live without carbon credits in their portfolios. SPDR S&P Oil & Gas Exploration & Production ETF (XOP)Expense Ratio: 0.35%For adventurous investors looking for energy sector exposure, the SPDR S&P Oil & Gas Exploration & Production ETF (NYSEARCA:XOP) is one of the best ETFs to buy. XOP can be great when oil prices are trending higher because exploration and production stocks are typically more correlated to crude prices than integrated oil companies.XOP does come with the disclaimer that, as is the case throughout financial markets, there is no such thing as a free lunch. Compared to traditional energy funds that are heavily allocated to stocks like Exxon Mobil (NYSE:XOM) and Chevron (NYSE:CVX), XOP is significantly more volatile.The added volatility gets compounded when oil prices decline. When that happens, XOP and rival exploration and production ETFs often produce losses that far exceed those of basic energy ETFs. Direxion Daily S&P Biotech Bull 3X Shares (LABU)Expense Ratio: 1.12%Like the aforementioned QID, the Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU). In the case of LABU, this leveraged funds tries to deliver triple the daily returns of the S&P Biotechnology Select Industry Index, so if that index rises by 1% on a particular day, LABU should jump by 3%.LABU is one of the best ETFs for risk tolerant because it amplifies the combination of biotechnology and volatility. Data confirm as much. Over the past month, LABU is one of Direxion's most volatile bullish leveraged ETFs, a status LABU frequently attains. * The 10 Best Stocks to Buy for May LABU is also one of the best ETFs for aggressive traders to deploy during biotechnology earnings season and around news events such as drug approvals and industry consolidation. What that means is traders should treat LABU like the short-term instrument it is. VanEck Vectors ChinaAMC SME-ChiNext ETF (CNXT)Expense Ratio: 0.65%Chinese small-caps probably are not the asset class for your retirement portfolio, but the VanEck Vectors ChinaAMC SME-ChiNext ETF (NYSEARCA:CNXT) is one of the best ETFs for investors seeking tactical exposure to the world's second-largest economy. CNXT fills some useful voids in international portfolios because many traditional China funds focus on large caps whereas this fund focuses on mid- and small-cap stocks.CNXT's underlying index "tracks the performance of the 100 largest and most liquid China A-share stocks listed and trading on the Small and Medium Enterprise ("SME") Board and the ChiNext Board of the Shenzhen Stock Exchange," according to VanEck.The weighted average market value of CNXT's 100 holdings is $12.8 billion, putting the fund just inside large-cap territory, but that number is still well below the average market caps found on holdings in traditional China ETFs.CNXT can be a bumpy ride. The fund is up 20% year-to-date, but that's after shedding 18% over the past month.As of this writing, Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Strong Buy Stocks That Tick All the Boxes * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund * 5 Tech ETFs to Plug In to Big Profits Compare Brokers The post 7 ETFs for Investors With a Gambler's Spirit appeared first on InvestorPlace.
Leveraged biotechnology exchange traded funds (ETFs) are known to make big moves, but sometimes those moves are not always about price action. What Happened Entering Monday, the Direxion Daily S&P Biotech ...
As the first quarter of 2019 has come to a close, these 10 ETFs and ETNs have led this investment category in gains for the first three months of this year. As you can see from the list, exchange traded products tied to the price of oil were among the top performers, as crude prices surged on production cuts.
As the first quarter of 2019 draws to a close, leveraged exchange-traded fund (ETF) traders have seen oil and technology take the top spots for year-to-date gainers. 2019 started off strong for U.S. equities–the ...
With markets still rebounding from late-2018’s sell-off and first-quarter earnings quickly approaching, we thought it would be a good time to take a look at which thematic ETFs among Direxion’s leveraged catalog have so far shown the strongest results on the year. Past performance is not indicative of future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.
The Zacks Analyst Blog Highlights: Direxion Daily S&P, Direxion Daily Regional Banks, Direxion Daily Aerospace, Direxion Daily Industrials and Direxion Daily Small Cap
We have highlighted six leveraged ETFs that have piled up exceptional returns in the first month of 2019 given that Wall Street made a sharp turnaround, posting the best month in many decades.
Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. The best biotech ETFs are diverse, with less volatility.
We have highlighted nine ETFs that have piled up exceptional returns to start 2019 and will continue to be investors' darlings provided the sentiments remain the same.
Biotechnology stocks and the related exchange traded funds are off to sizzling starts in 2019. The soaring start to 2019 by the equal-weight S&P Biotechnology Select Industry Index is lifting the fortunes of the Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU). LABU, one of the largest leveraged biotechnology ETFs, is up more than 45 percent year-to-date, easily making it ne of Direxion's best-performing leveraged bullish ETFs in the month of January.
According to a report by the Silicon Valley Bank, biopharma deals in 2018 totaled $49 billion and more mergers in 2019 could continue providing growth in the industry, fueling ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) . This was evident early in the new year as the biopharma space began 2019 with Bristol-Myers Squibb offering $74 billion to take over Celgene--a deal that could allow Bristol to become a top five pharmaceutical giant. RBC Capital Markets analyst Brian Abrahams said there's "a strong need to diversify around maturing franchises with (patents expiring) and biotech valuations having come down.
Stocks rallied Wednesday, a day after one of the most contentious midterm elections in U.S. history. In Tuesday's midterm elections, Democrats emerged with control of the House while Republicans maintained control of the Senate. Among the winning exchange traded funds Wednesday were biotechnology funds, including the SPDR S&P Biotech ETF (XBI) , which takes an equal-weight approach to the biotech space.
Biotechnology stocks and exchange traded funds participated in the October broader market swoon, punishing funds such as the Direxion Daily S&P Biotech Bull Shares (LABU) in the process. LABU, which takes the 3x or 300% daily performance of the S&P Biotechnology Select Industry Index, is attempting to reverse its October slide this month and is off to a good start with a November gain of about 14%. The slump in once hot biotechnology ETFs could present investors with a buying opportunity.
Few asset classes are as seductive as leveraged exchange-traded funds (ETFs). Other than leveraged ETFs, where else in the fund universe (without using options) can investors make a bet on a simple index, such as the S&P 500 or Nasdaq-100 Index, and amplify those benchmarks’ gains to the tune of 200% or even 300% in a single trading day?
Usually, when investors add biotechnology stocks to their portfolios, they feel confident about risk. When they want to reduce risk, biotech names are the first to go. LABU (3X Biotech Bull) and LABD (3X Biotech Bear) can help you stay risk-on or risk-off.